Overcoming acquired resistance to PD-1 inhibitor with the addition of metformin in small cell lung cancer (SCLC)
Authors (first, second and last of 12)
Since its inception in 1976, Cancer Immunology, Immunotherapy (CII) has reported significant advances in the field of tumor immunology. The journal serves as a forum for new concepts and advances in basic, translational, and clinical cancer immunology and immunotherapy. CII is keen to publish broad-ranging ideas and reviews, results which extend or challenge established paradigms, as well as negative studies which fail to reproduce experiments that support current paradigms, and papers that do succeed in reproducing others’ results in different contexts. Cll is especially interested in papers describing clinical trial designs and outcome regardless of whether they met their designated endpoints or not, and particularly those shedding light on immunological mechanisms.
CII is affiliated with the Association for Cancer Immunotherapy (CIMT), Canadian Cancer Immunotherapy Consortium (CCIC), The Japanese Association for Cancer Immunology (JACI), Network Italiano per la Bioterapia dei Tumori (NIBIT), and Sociedad Española de Inmunologia-Grupo Española de InmunoTerapia (SEI-GEIT).
CIMT: http://www.cimt.eu/home
CCIC: http://www.immunotherapycancer.ca/
JACI: http://www.jaci.jp/eng/index.html
NIBIT: http://www.nibit.org/index.php
SEI-GEIT: http://www.inmunologia.org/grupos/home.php?UpOm5=M&Upfqym5uom=GK
CITIM: http://www.canceritim.org 94% of authors who answered a survey reported that they would definitely publish or probably publish in the journal againJournal information
- Editor-in-Chief
-
- Haidong Dong
- Publishing model
- Hybrid. Learn about publishing OA with us
Journal metrics
- 5.442 (2019)
- Impact factor
- 4.781 (2019)
- Five year impact factor
- 44 days
- Submission to first decision
- 211 days
- Submission to acceptance
- 425,640 (2019)
- Downloads
Latest issue
Latest articles
-
-
Notch signaling defects in NK cells in patients with cancer
Authors (first, second and last of 10)
-
Novel adjuvant dendritic cell therapy with transfection of heat-shock protein 70 messenger RNA for patients with hepatocellular carcinoma: a phase I/II prospective randomized controlled clinical trial
Authors (first, second and last of 16)
-
Tuberculosis following programmed cell death receptor-1 (PD-1) inhibitor in a patient with non-small cell lung cancer. Case report and literature review
Authors (first, second and last of 10)
-
Efficacy and safety of sintilimab in combination with chemotherapy in previously untreated advanced or metastatic nonsquamous or squamous NSCLC: two cohorts of an open-label, phase 1b study
Authors (first, second and last of 16)
Journal updates
-
COVID-19 and impact on peer review
As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.
-
Announcing new Editor-in-Chief: Dr. Haidong Dong
The journal is pleased to announce Dr. Haidong Dong has been named the new Editor-in-Chief of Cancer Immunology, Immunotherapy, effective January 1, 2020.
Societies, partners and affiliations
About this journal
- Electronic ISSN
- 1432-0851
- Print ISSN
- 0340-7004
- Abstracted and indexed in
-
- AGRICOLA
- BIOSIS
- Biological Abstracts
- CNKI
- Chemical Abstracts Service (CAS)
- Current Contents/ Life Sciences
- Dimensions
- EBSCO Academic Search
- EBSCO Biomedical Reference Collection
- EBSCO Discovery Service
- EBSCO STM Source
- EMBASE
- Elsevier Biobase
- Google Scholar
- Institute of Scientific and Technical Information of China
- Japanese Science and Technology Agency (JST)
- Journal Citation Reports/Science Edition
- Medline
- Naver
- OCLC WorldCat Discovery Service
- Pathway Studio
- ProQuest Biological Science Database
- ProQuest Central
- ProQuest Health & Medical Collection
- ProQuest Health Research Premium Collection
- ProQuest Immunology Abstracts
- ProQuest Medical Database
- ProQuest Natural Science Collection
- ProQuest Pharma Collection
- ProQuest Public Health Database
- ProQuest SciTech Premium Collection
- ProQuest-ExLibris Primo
- ProQuest-ExLibris Summon
- Reaxys
- SCImago
- SCOPUS
- Science Citation Index
- Science Citation Index Expanded (SciSearch)
- Semantic Scholar
- TD Net Discovery Service
- UGC-CARE List (India)
- Copyright information
